NCT04648280招募中1 期
A Multicenter, Open-label, Single-arm Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Fostemsavir in Combination With Optimized Background Therapy (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their Current Combination Antiretroviral Therapy (cART) and Have Dual- or Triple-class Antiretroviral (ARV) Resistance
PENTA Foundation10 个研究点 分布在 3 个国家目标入组 60 人开始时间: 2022年6月30日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 10
- 主要终点
- Ctau of temsavir across weight bands
研究概览
简要总结
In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and swallowability of formulation among the pediatric population. The dose selection of FTR for children and adolescents ≥20kg utilized a population pharmacokinetic (POP PK) model-based approach to achieve similar adult TMR exposures following FTR 600mg BID administration with combination therapy that was demonstrated to be safe and effective in the FTR Phase 3 BRIGHTE study in HTE patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female HIV-1 infected paediatric participants from 6 years old and weighing at least 20 kg to less than 18 years of age.
- •Antiretroviral-experienced with documented historical or baseline resistance to one or more agents in at least two classes. All resistance has to be properly documented.
- •Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 1000 c/mL (first value from Investigator within 6 months of screening visit, with the second value obtained from Screening labs, without a decline greater than 1 log10, and no value <1000 in between).
- •Documented resistance to at least one component of the current failing regimen per screening resistance testing.
- •Must have at least 1 fully active and available agent in 2 or more ARV classes, based on current and/or documented historical resistance testing, taking into account tolerability, and other safety concerns. At least two fully active agents must be a part of the initial OBT to be paired with FTR.
- •Girls who have reached menarche must have a negative pregnancy test at screening, not be breastfeeding, and be willing to adhere to effective methods of contraception if sexually active. All participants (male or female) have to agree with recommendations for effective contraception.
排除标准
- •Medical History and Concurrent Diseases:
- •Unable to comply with dosing requirements (to swallow solid pharmaceutical form of the investigational medicinal product)
- •Unable to comply with study visits
- •Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might interfere with drug absorption or render the participant unable to take oral medication.
- •Any clinical condition (including but not limited to recreational drug use) or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study
- •Pregnancy and breastfeeding
- •Physical and Laboratory Test Findings:
- •Chronic untreated Hepatitis B virus (HBV) (however, participants with chronic treated HBV or spontaneously remitted HBV are eligible)
- •HIV-2 infection
- •Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥1.5xULN (with>35% direct bilirubin)
- •History of unstable liver disease, decompensated cirrhosis, or known biliary disorder
- •History of congestive heart failure, or congenital/acquired prolonged QT syndrome/other cardiac diseases predisposing to prolonged QTc
- •Hemoglobin < 8.0 g/dL
- •Platelets < 50,000 cells/mm3
- •Confirmed QTcF value > 450 msec, regardless of sex, at Screening or Day 1
- •Current (defined as taking the medication within 14 days of Day 1) or anticipated treatment with medication considered prohibited or restricted as per Appendix II. Certain medication will be carefully evaluated as acceptable, see Appendix II.
- •Participation in an experimental drug and/or HIV-1 vaccine trial(s) within the previous 30 days
- •Child in governmental care, e.g. child is a ward of the state. Note: This criterion does not apply if the child is officially adopted by a family/guardian.
研究组 & 干预措施
Fostemsavir
Experimental
Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
干预措施: Fostemsavir (Drug)
结局指标
主要结局
Ctau of temsavir across weight bands
时间窗: at week 1, 4, 12, 24, 48
Occurrence of the following events through Week 24
时间窗: 24 weeks
AUC(0-tau)
时间窗: at week 1, 4, 12, 24, 48
Cmax
时间窗: at week 1, 4, 12, 24, 48
次要结局
- Change in log10 HIV-1 RNA from baseline(at 24 weeks and 48 weeks)
- Occurrence of WHO 3 or 4 defining events, or death(up to 156 weeks)
- Proportion of patients with HIV-1 RNA <50 copies/mL(at 24 weeks and 48 weeks)
- Occurrence of: AEs, treatment-related AEs, AEs of Grade 3 or higher, serious AEs, and AEs leading to premature study treatment discontinuation.(at Week 48 and at the end of Study)
- efficacy of fostemsavir plus OBT(up to 156 weeks)
- Emergence of genotypic or phenotypic resistance to Temsavir and components of OBT(up to 156 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
A Study of CM310 in Children Patients With Moderate-to-severe Atopic DermatisAtopic DermatitisNCT05579925Keymed Biosciences Co.Ltd24
已完成
1 期
Study of CM310 in Children Subjects With Moderate-to-severe Atopic DermatisAtopic DermatitisNCT06162507Keymed Biosciences Co.Ltd24
尚未招募
不适用
Trial for MicroPort's DCBCoronary Artery In-stent RestenosisNCT04386213Shanghai MicroPort Medical (Group) Co., Ltd.216
已完成
2 期
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4Hepatitis C, ChronicNCT01057667Hoffmann-La Roche168
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45